Neurodegeneration
Alzheimer's Disease
Pre-clinicalActive
Key Facts
About Keltic Pharma Therapeutics
Keltic Pharma Therapeutics is a private, preclinical-stage biotech company developing a proprietary drug discovery platform called PEPSMOL©. This platform aims to create 'synthetic biologics' to target hard-to-drug GPCRs, with initial in-house programs targeting severe asthma, malaria, Alzheimer's disease, and schizophrenia. The company, founded by three renowned University of Glasgow professors, is pre-revenue and has secured non-dilutive grant funding, including a SMART Grant from Innovate UK in 2024, to advance its platform and pipeline.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| MK-6240 (florquinitau) | Lantheus Medical Imaging | Regulatory Filing |
| NAV-4694 (flutafuranol) | Lantheus Medical Imaging | Phase 3 |
| LNTH-2620/PI-2620 | Lantheus Medical Imaging | Phase 3 |
| itMSCs | Stemedica Cell Technologies | Clinical Development |